Abstract
Introduction

38
The use of animals to evaluate the safety of new drugs is an integral part of the regulatory 39 research and development process (1,2). Established at a time when laboratory animals were one of 40 the most complex systems available, they are still considered as the gold standard today. Yet, despite 41 their apparent value as a drug testing system to predict safety and efficacy in humans, scientists are 42 increasingly aware of their considerable drawbacks and limited predictivity (3) (4) (5) (6) . 43
While no apparent toxicity in poorly predictive animal models can lead to possible harm to 44 patients, false toxic signals might prevent potentially safe drugs from reaching patients. This constitutes 45 an unreasonable loss of resources for drug developers. Concomitantly, limitations in animal models of 46 efficacy showing an overly optimistic interpretation of efficacy will lead to clinical trials with drugs that 47 have a modest effect at best or are completely ineffective at worst (5,7). 48
We previously assessed the value of regulatory safety studies in a public-private research 49 consortium which consisted of pharmaceutical company stakeholders, the Dutch regulatory agency and 50 academia (8). This partnership was unique in that it allowed proprietary data to be used for our primary 51 analyses, which could then be presented in an aggregated, anonymised fashion to propose policy 52 changes (9-13). A key finding of these studies was that despite non-human primate (NPH) models 53 having the closest biological resemblance to humans, their indiscriminate use in the safety testing of 54 new biotechnology products (e.g. mAbs) as well as in demonstrating the similarity of biosimilar to 55 reference products often adds limited value to the preclinical package. When taken altogether, these 56 results suggest the mandatory use of animal safety testing according to current guidelines should be 57
reconsidered. 58
Contrary to safety assessment, the evaluation of efficacy is not subject to formalized guidance or 59 regulations since each new drug warrants a tailor-made approach based on its mechanism of action 60 and indication (14). Consequently, predefining which assays or models to be used to test new drugs' 61 efficacy, as done for safety, could jeopardise innovative companies' ability to develop such drug-specific 62 strategies. 63
Nevertheless, most late-stage clinical trials, which are often based on efficacy data from animal 64 studies fail due to the lack of efficacy (15) (16) (17) (18) (19) . The low internal validity (i.e. the methodological qualities 65 of an experiment, such as randomisation and blinding) of animal research has been frequently 66 4 suggested as a likely cause for such poor translation to the clinic (20) (21) (22) (23) (24) . Initiatives aimed at improving 67 design and reporting standards of preclinical studies, such as the ARRIVE guidelines, now allow 68 researchers to effectively address these issues (25) . 69
The inadequate assessment of the external validity of efficacy models (i.e. how well animal 70 results are generalisable to the human situation) is also an important factor for poor translation (4). 71
Currently, drug developers frequently rely on the well-established criteria of face, construct and 72 predictive validity (26, 27) . Because none of these criteria goes beyond the level of scientific concept -73 they are not integrated and do not present a systematic way to assess the ability of an animal model to 74 predict drug efficacy in humans, they are highly subject to user interpretation. The absence of 75 standardisation results in animal models being assessed by different disease parameters, which further 76 complicates a scientifically relevant comparison. 77
Previous attempts to formalize the assessment of external validity have introduced systematic 78 ways to score validity, but fail to capture most of the characteristics potentially relevant for the 79 demonstration of efficacy (e.g. genes, biomarkers, histology) to make them informative and usable to 80 this end (28, 29) . 81
82
The Framework to Identify Models of Disease (FIMD)
83
The existing approaches for assessing external validity cannot be used by researchers to find 84 what is the most relevant model to demonstrate the efficacy of a drug based on its mechanism of action 85 and/or indication. Here, we present a method to assess the external validity of efficacy models as well 86 as to integrate the different aspects needed to establish preliminary efficacy in an animal model -the 87
Framework to Identify Models of Disease (FIMD). A 'model of disease' is here used for any animal 88 model that simulates a human condition for which a drug can be developed. Eight relevant aspects 89 were identified based on an exploratory literature search (see Supplementary Information S1) and used 90 to draft questions related to the different facets of disease simulation (Fig 1) . 91 This results in a better understanding of the pathways that are involved in the disease pathophysiology 100 of a model when compared to humans. Consequently, companies with extensive animal data from failed 101 projects can easily perform a read-across of their models to inform the choice of future programmes. In 102 addition, all interventional drug studies in the pharmacological validation also include a quality 103 assessment of the study design and reporting adapted from the ARRIVE guidelines (see Supplementary 104
Information S2). 105
To facilitate the comparison between animal models in the same indication and ultimately, the 106 choice of the best fit for investigating a drug's efficacy, we developed a weighting and scoring system 107 (see Supplementary Information S3). This system includes a Disease Classification Flowchart (DCF) 108 for the selection of the adequate weighting system since the relevance of each aspect might differ for 109 different indications (e.g. genetic disorder vs. bacterial infection). 110
The weighting and scoring system is an indication of the degree to which a model simulates the 111 human condition. While it is admittedly arbitrary, it allows researchers to identify the strengths and 112
weaknesses of an animal model at a glance. The underlying data will further determine which model is 113 the most relevant for a given drug. This means the best fit will not necessarily be the model with the 114 highest score but rather the model that more closely mimics the pathways involved in the mechanism 115 of action of a drug. 116
Next to the weighting and scoring system, two factors were created to further contextualise the 117 final score: the uncertainty factor and the similarity factor. The uncertainty factor differentiates between 118 models that are not well-characterised and models that scored low for not simulating completely or 119 partially many aspects of the human condition. The similarity factor differentiates between two models 120 with similar final scores but that score differently in the same aspects of validation. 121
All these features of the framework were further refined the framework, we conducted a web-122 based survey with experts from academia, industry and regulatory agencies (see Supplementary  123 Information S4). to completely mimic the human condition, it is important to identify which aspects they can reproduce 136 and to which extent. Therefore, we established four levels of confidence in the validation of animal 137 models in their context of use based on the percentage of definite answers to the eight validation 138 sections (see Table 1 ). A 'definite answer' is defined as any answer except for 'unclear', which is used 139 to indicate the absence of evidence in the literature or conflicting results. 140 141 
Applications and Final Considerations
145
The product of FIMD is a validation sheet of an animal model for an indication, which provides 146 the necessary information for its assessment as a potential model to demonstrate a drug's efficacy (see7 Supplementary Information S4, S5 and S6). Based on a drug's mechanism of action, models can be 148 first discriminated by assessing whether the correlation between animal and human drug studies of 149 relevant pathways is available in the pharmacological validation section. The other sections provide 150 additional information, such as the presence of relevant genes and biomarkers. Finally, the validation 151 level is an index of the reliability of a model's overall ability to mimic the human condition, serving as 152 another layer to further differentiate potentially useful from non-useful models. The combination of all 153 these features allows researchers to select, among a plethora of models, the model most likely to 154 correctly predict the efficacy of a drug in humans. An example of the application of FIMD is presented 155 in Box 1, in which the Golden Retriever Muscular Dystrophy (GRMD) dog emerges as a significantly 156 better model than the more commonly used mdx mouse. 157
An important application for FIMD is on the approval of animal studies by Institutional Review 158 Boards (IRBs). IRBs often base their decisions on unpublished animal studies with poor internal validity 159 (32). FIMD presents an opportunity to assess the validity of a specific model for efficacy assessment 160 while also providing insights from earlier research. By using the validation sheet of models used to 161 support the first-in-human trials, IRBs can, for the first time, tackle all these issues at once. FIMD 162 provides the background for the choice of the model(s), allowing IRBs to accurately assess whether the 163 data generated is likely to be translatable to the clinic. 164
Since FIMD includes a quality assessment of all studies included in the pharmacological validated 165 and require that these be published, it promotes further scientific scrutiny in peer-review processes. 166
Nonetheless, it only includes publicly available information. Given the publication bias often reported in 167 animal and clinical research, it is possible that results from the pharmacological validation might be 168 skewed (4, 33, 34) . Nonetheless, there is a growing demand for the pre-registration of preclinical studies 169 and the publication of their results (32, 35, 36) . With the establishment of registries like 170 PreclinicalTrials.eu, the overall publication bias is expected to be reduced and therefore, so will be its 171 impact on FIMD (37). Furthermore, with the collection of validation sheets of models of efficacy, it will 172 be possible to make them available in an open database of validated models in which users can, based 173 on their drug's characteristics (e.g. mechanism of action or intended indication), find the best model to 174 evaluate the efficacy of a drug before planning an animal experiment. 175 FIMD can simplify the interaction between companies and regulatory agencies as it allows a more 176 objective and science-based discussion on the choice of an animal model. This potentially prevents 177 8 efficacy studies on non-relevant models, effectively contributing to the reduction of the use of animal 178 models in the context of the 3R's. By assessing the degree to which a model mimics a human condition, 179 FIMD facilitates the choice of a relevant model for efficacy assessment and promotes the conduct of 180 efficacy studies whose results will more likely translate to the clinical situation. 181
[BOX 1: Using FIMD to assess and compare efficacy models] 182
We used a simplified version of FIMD to test its applicability in two indications with two models 183 each (more information available in Supplementary Information S4). Duchenne Muscular Dystrophy 184 (DMD) was chosen because it is caused by mutations in a single gene and for the limited availability of 185 effective therapies (38). Type 2 Diabetes (T2D) was chosen as a disease which has a complex 186 pathophysiology and for which an extensive set of therapies is available (39). 187
In DMD, the models were chosen based on being either commonly used (mdx mouse) or for 188 The GRMD dog scores better in the epidemiological, pathophysiological and histological sections 197 while the mdx mouse does so in the pharmacological and endpoints sections. The GRMD dog mimics 198 the natural history of the disease, symptoms (e.g. muscle wasting) and histopathological features (e.g. 199 muscle regeneration) better than the mdx mouse. Especially for drugs which aim to slow down muscle 200 degeneration or delay the disease onset, the GRMD dog is likely to generate more translatable data 201 than the mdx mouse. 202
The difference in the pharmacological and endpoints sections stems mostly from the uncertainty 203 factor, which is 20% and 5.7% for the GRMD dog and the mdx mouse respectively. Since most drug 204 screening studies are done in mdx mice, there are more studies available for the pharmacological 205 validation. However, there are no published studies in GRMD dogs for most drugs tested in humans. 206
The only published study that assessed a functional outcome, did so in sedated dogs, which reduced 207 9 the score of the endpoints validation. Hence, a comparison between these models in these two sections 208 is unlikely to be informative. 209
For T2D, the Zucker Diabetic Fatty (ZDF) rat and the db/db mouse were both chosen for being 210 routinely used in drug screening for antidiabetic drugs. A total of 195 publications were included for the 211 ZDF rat and 282 for the db/db mouse. The relative scores per parameter are presented in Fig 3. 
